Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab with Gemcitabine/Carboplatin in advanced LELC
NCT04312204Phase 2Unknown
- Start
- Mar 2020
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of sintilimab in Primary Pulmonary Lymphoepithelioma-like Carcinoma (PLELC). Status: unknown.
02
Drugs
sintilimab
03
Conditions
Primary Pulmonary Lymphoepithelioma-like Carcinoma (PLELC)
Beyond the preview
Go deeper on NCT04312204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04312204.